Brain Dopamine Function in Adults With ADHD (Brookhaven)
This study has been completed.
Sponsor:
University of California, Irvine
Collaborators:
Mount Sinai School of Medicine
Duke University
Information provided by:
University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00580814
First received: October 4, 2007
Last updated: April 6, 2011
Last verified: April 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to investigate the functional state of dopamine cells and the dopamine transporter in ADHD subjects and controls to assess the effects of chronic methylphenidate treatment on dopamine cell function and dopamine transporter levels in ADHD subjects.
Condition | Intervention |
---|---|
Attention Deficit Hyperactivity Disorder |
Drug: Methylphenidate |
Study Type: | Interventional |
Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
Official Title: | Brain Dopamine Function in Adults With ADHD |
Resource links provided by NLM:
MedlinePlus related topics:
Attention Deficit Hyperactivity Disorder
Drug Information available for:
Dopamine
Dopamine hydrochloride
Methylphenidate
Methylphenidate hydrochloride
U.S. FDA Resources
Further study details as provided by University of California, Irvine:
Primary Outcome Measures:
- Two PET scans.One at baseline and the second a year later. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Enrollment: | 24 |
Study Start Date: | February 2006 |
Study Completion Date: | April 2009 |
Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Methylphenidate
Methylphenidate
Eligibility
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Must give informed consent
- Must be between the ages of 18 and 45 years old.
- Must have a confirmed diagnosis of ADHD
- Must have scored on a rating scale that indicate a significant level of symptom severity.
- Must have a childhood history of ADHD must be documented using established test criteria.
- Must have had no previous medication treatment for ADHD except for a short term treatment period of less than three months, which should have occurred at least six months prior to the study.
- Must have an interest in receiving long-term medication treatment for ADHD.
Exclusion Criteria:
- Must not test positive for psychoactive drugs during a urine drug screen.
- Must not be pregnant.
- Must not be breastfeeding.
- Must have no past or present history of dependence on alcohol or other drugs of abuse except nicotine or caffeine.
- Must have no past or present history of a psychiatric disorder except ADHD.
- Must have no medical illness that may affect brain function.
- Must not have taken medication that may affect brain function.
- Must not have had head trauma with loss of consciousness (> 30 minutes).
- Must not have significant anxiety or depression as determined by an established test.
- Must have no history of a significant learning disability.
- Must have no history of cardiovascular or endocrinological disease.
- Must have no history of coagulation disorder.
- Must have no history of sensitivity to lidocaine and/or prilocaine.
- Must have no history of claustrophobia.
- Contraindication to MRI environment (presence of any implanted metallic objects such as cardiac/neural pacemakers, defibrillators, aneurysm clips, certain heart valves, spinal nerve stimulators, artificial joints/limbs, shrapnel/bullets, metal fragments in their eyes, cochlear implants, hearing aids, dental implants).
- Must have no history of glaucoma.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00580814
Locations
United States, California | |
UCI Child Development Center | |
Irvine, California, United States, 92612 |
Sponsors and Collaborators
University of California, Irvine
Mount Sinai School of Medicine
Duke University
Investigators
Principal Investigator: | Tim Wigal, Ph.D. | UC Irvine |
More Information
No publications provided
Keywords provided by University of California, Irvine:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
Responsible Party: | Brookhaven National Laboratory, Stonybrook State University of New York |
ClinicalTrials.gov Identifier: | NCT00580814 History of Changes |
Other Study ID Numbers: | CORIHS ID# 20055906 |
Study First Received: | October 4, 2007 |
Last Updated: | April 6, 2011 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, Irvine:
Brookhaven ADHD Dopamine methylphenidate PET |
Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Mental Disorders Diagnosed in Childhood Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Dopamine Dopamine Agents Methylphenidate Cardiotonic Agents Cardiovascular Agents |
Therapeutic Uses Pharmacologic Actions Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Central Nervous System Stimulants Central Nervous System Agents |
ClinicalTrials.gov processed this record on October 17, 2012